Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and eff
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... an intimidating job description: ensure products meet quality standards ... tight budgets and escalating regulations, quality leaders also have ... costs and risk. Those who don,t effectively ... quality function as well as marketplace failure and regulatory ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Week in Review: The Latest from PhRMA 2
... 17 Regado Biosciences, a privately held company leading the ... David J. Mazzo , PhD, President and CEO, will be presenting ... in Boston, Massachusetts . Dr. Mazzo,s presentation will be given ... in the Robinson Room and will include an overview of ...
... June 17 Salvin Dental Specialties, Inc. and LifeNet Health ... advance LifeNet Health,s OraGraft™ allograft products in the dental market. , ... The two companies ... the existing relationship between these two companies, which provides LifeNet Health ...
Cached Medicine Technology:Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 2Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 3LifeNet Health and Salvin Dental Specialties Announce Partnership 2LifeNet Health and Salvin Dental Specialties Announce Partnership 3
(Date:3/29/2015)... (PRWEB) March 29, 2015 Youth Villages ... counties in Oregon to assess the feasibility of implementing ... emotional and behavioral problems and their families. , Third ... select participants that will be provided technical assistance throughout ... counties join six other national awardees chosen by Third ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... W. Brickner, “and as we learn more about the ... , In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... homeostatic health, or endo-healing, is celebrated. Publius, of The ... four 2015 National Institutes of Health (PubMed) cannabinoid system ...
(Date:3/28/2015)... AZ. (PRWEB) March 28, 2015 Could ... to a new study by researchers at ... , Produced with the support of the Coffee and ... journal Molecular Psychiatry this past fall, the study—one of ... meta-analysis of genomic data from more than 120,000 regular ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... memory in Alzheimer disease mice , Overactivation of ... formation, has been linked to Alzheimer disease. Ottavio Arancio ... shown that two different drugs that inhibit calpains can ... (APP/PS1 mice), leading them to suggest drugs that target ...
... Goals of All Parties -, MONETT, Mo., July ... ), a leading provider of integrated technology solutions,and data ... agency outsourcing solution has been bought by the,business line,s ... the,transaction were not disclosed., Banc Insurance Services, Inc. ...
... ABABA, Ethiopia, July 1 The U.S.,Agency for International ... the USA to combat HIV/AIDS in Ethiopia. The program ... vital medical,services and improve existing care and prevention programs ... and Adama. It will,also build community networks by means ...
... rise with temperatures , , TUESDAY, July 1 (HealthDay News) -- ... heat-related health issues because their bodies don,t cool down as ... not feel hot when the temperature is dangerously high and ... bodies have lost too much water," Dr. John B. Murphy, ...
... guide Foundation,s efforts, including polio,eradication, EVANSTON, Ill., July ... office on July 1 as chair of The,Rotary Foundation ... polio in its last remaining strongholds -- which include ... Foundation this year," said Majiyagbe.,"It is abundantly clear to ...
... SALT LAKE CITY, July 1 Dynatronics,Corporation (Nasdaq: ... a,letter from NASDAQ stating that for the last 30 ... has closed below the minimum $1.00 per,share requirement for ... company will be given 180 calendar days, or until ...
Cached Medicine News:Health News:JCI online early table of contents: July 1, 2008 2Health News:JCI online early table of contents: July 1, 2008 3Health News:JCI online early table of contents: July 1, 2008 4Health News:JCI online early table of contents: July 1, 2008 5Health News:JCI online early table of contents: July 1, 2008 6Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 2Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 3Health News:USAID Announces Youth-Focused HIV/AIDS Programs in Ethiopia 2Health News:Extreme Heat a Deadly Risk for Older Adults 2Health News:The Rotary Foundation's First African Trustee Chair Takes Office 2Health News:The Rotary Foundation's First African Trustee Chair Takes Office 3Health News:Dynatronics Receives NASDAQ Minimum Bid Price Deficiency Letter 2
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
Medicine Products: